The anti-tumor efficacy of ENPP3 blockade was abrogated by IFNAR1 inhibition.<h4>Conclusion</h4>ENPP3 is a hypoxia-driven, cGAMP-targeting innate immune checkpoint in ccRCC. This evidence concerns the gene IFNAR1 and nonpapillary renal cell carcinoma.